Lomustine

SKU: orb1308063

Description

Lomustine (NSC-79037) is a nitrosourea alkylating agent used in research for its antitumor properties. It is applied in studies of gliomas, lymphomas, and other cancers, with established protocols for both in vitro cytotoxicity assays and in vivo tumor model experiments.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 13010-47-4
• MW: 233.7
• Purity: 99.86% (May vary between batches)
• Formula: C₉H₁₆ClN₃O₂
• SMILES: N(C(N(CCCl)N=O)=O)C1CCCCC1
• Target: Autophagy,DNA Alkylator/Crosslinker,DNA Alkylation,Apoptosis
• Solubility: DMSO:250 mg/mL (1069.75 mM);Ethanol:< 1 mg/mL (insoluble or slightly soluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (8.56 mM);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• In Vivo:
  Lomustine can cause delayed, cumulative dose-related, chronic hepatotoxicity that is irreversible and can be fatal. Lomustine could result in infrequent severe hematological toxicity in cats with spontaneously arising tumors, and the incidence of either grade III or IV neutropenia and thrombocytopenia is 4.1% and 1.0%, respectively. Lomustine trends toward a greater likelihood for progressive neutropenia and statistically significant higher response rates in cats with spontaneously arising tumors.
• In Vitro:
  Lomustine inhibits the growth of ZR-75-1 and U373 with IC50 of 12 μM and 15 μM, respectively. Lomustine reduces the level of expression of the DNA repair protein O6-alkylguanine-DNA alkyltransferase. Lomustine (420 μM) triggers apoptosis through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively, in both medulloblastoma and normal human epithelial and fibroblast cells. Lomustine induces cell cycle delay in G2/M phase in medulloblastoma cells and up-regulates p21 protein level in a p53-independent manner in HFSN1 cells.
• Cell Research:
  Cell lines are routinely grown as monolayers in DMEM supplemented with 10% foetal calf serum, 25 mm HEPES, glutamine and penicillin/streptomycin. Cytotoxicity studies are carried out in HEPES-free medium in a 5% CO2 atmosphere. 750-1000 cells/well are plated in 96 well plates and after overnight incubation are treated for 2 hours with or without 33 μM BG. Temozolomide or CCNU is then added for 1 hour in the same medium, the final DMSO concentration not exceeding 1%. The cells are grown for a further 7 days in fresh medium and assayed for protein content by the NCI sulphorhodamine assay; growth studies show that cells are in log phase growth during the assay period. For the repeat temozolomide dosing schedule cells are given consecutive 24 hours treatments, with fresh medium each day. Assays are carried out at least in duplicate.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Crosslinker, DNAAlkylation, DNAAlkylator, DNA Alkylating, DNA Alkylation, DNA Alkylator, DNA Alkylator/Crosslinker, CCNU, Autophagy, Apoptosis, NSC 79037, NSC79037, NSC-79037, Lomustine, inhibit, Inhibitor, Stathmin-4

Compound Identifiers

PubChem CID

3950